LabCorp

Working With Cancer: from Davos to the Super Bowl

Retrieved on: 
Tuesday, January 31, 2023
MSD, Health, Adobe, LVMH, Bank of America, Meta, Citigroup, Publicis, Clear channel, Super Bowl, Zeta, Social change, Fox, World Economic Forum, LabCorp, BNP Paribas, Caregiver, Mass media, Walmart, Roku, Omnicom Group, Sanofi, Microsoft, Bank, Workplace, Patient, Super Bowl commercials, NCM, Unilever, Movement, IHeartRadio, BT, Creativity, Disney–ABC Domestic Television, Verizon Communications, NBCU, PepsiCo, AbbVie, World Cancer Day, Mobile phone, Medical imaging, Cancer, Paramount, TikTok

After being diagnosed and treated for cancer last year, Arthur Sadoun CEO of Publicis Groupe launched Working with Cancer at the World Economic Forum in Davos on 17th January.

Key Points: 
  • After being diagnosed and treated for cancer last year, Arthur Sadoun CEO of Publicis Groupe launched Working with Cancer at the World Economic Forum in Davos on 17th January.
  • Today the program is an alliance of major international companies united by a pledge to create an open, supportive and recovery-forward culture for cancer sufferers.
  • Doug McMillon, President & CEO Walmart: “Walmart is proud to partner with Working with Cancer and others to eliminate the workplace stigma of a cancer diagnosis.
  • Publicis Groupe will also contribute by becoming the first holding company to purchase and invest in a Super Bowl spot.

ProgenyHealth Appoints Susan Torroella as CEO to Lead the Company During its Next Stage of Growth

Retrieved on: 
Tuesday, January 17, 2023
LabCorp, Wellness Corporate Solutions, Ernst, MD, Torroella, Public sector, Woman, UnitedHealth Group, Growth, Fortune Small Business, Health, Ernst & Young Entrepreneur of the Year Award, Infant, Management, Mother, Progeny

PLYMOUTH MEETING, Pa., Jan. 17, 2023 /PRNewswire/ -- ProgenyHealth, LLC, a leading, tech-enabled women's healthcare company dedicated to Maternity and NICU Care Management, has announced the hiring of Susan Torroella as the company's new Chief Executive Officer. Ms. Torroella was chosen for the role by Dr. Ellen Stang, who founded the company and has served as CEO since its creation in 2003, and members of Progeny's Board of Managers. Dr. Stang will now serve as Executive Chairwoman in a strategic advisory role, as well as focusing her time on building a new ProgenyHealth Foundation.

Key Points: 
  • Ms. Torroella, who most recently served as President and CEO of ArmadaHealth, is known as an exceptionally strong leader with global experience across the healthcare spectrum.
  • With prior C-Suite level experience as a CEO, COO and President, she is well-positioned to drive further success for ProgenyHealth.
  • To come full circle and now lead ProgenyHealth, a leading national tech-enabled women's healthcare company in Maternity and NICU Care Management , is thrilling.
  • "With the value and impact ProgenyHealth is delivering, the company is on the cusp of a new phase of exponential growth.

Labcorp to Announce Fourth Quarter and Full Year 2022 Financial Results on February 16, 2023

Retrieved on: 
Wednesday, January 18, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, LH, Webcast, PIN, NYSE, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2022 before the market opens on Thursday, Feb. 16, 2023.
  • The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website .
  • The call will be webcast live on the Labcorp Investor Relations website .
  • To access the webcast recording, visit the Labcorp Investor Relations website .

Europe Medical Diagnostics Market Report 2022: Expansion of Medical Devices Industry Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Health, General Health, Immunoassay, Attention, COVID-19, POC, Synlab Group, Hematology, Pandemic, Government, Precision medicine, IVD, Coagulation, Infection, Diagnosis, Growth, Quest Diagnostics, Eurofins Scientific, Clinical chemistry, Urbanization, Sonic Healthcare, LabCorp, US, Pharmaceutical industry, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$104.01 billion in 2027, growing at a CAGR of 4.52%, for the time period of 2023-2027.
  • Factors such as rise in number of new cancer cases, expansion of medical device industry, growth in geriatric population, accelerating demand for In-Vitro Diagnostic (IVD) and rapid urbanization would drive the growth of the market.
  • As a result of this, the demand for immunoassays is rising, which is aiding the market growth of medical diagnostics in Europe.

Labcorp Declares Quarterly Dividend

Retrieved on: 
Thursday, January 12, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, LH, NYSE, Holding company, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.

Key Points: 

Labcorp (NYSE: LH), a leading global life sciences company, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 13, 2023, to stockholders of record as of the close of business on Feb. 23, 2023.

Global Non-invasive Cancer Diagnosis Market Analysis and Forecasts 2022-2028: Focus on Clinical Chemistry, Immunochemistry/Immunoassay, Molecular Diagnostics, and Other Clinical Instruments - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Health, Oncology, Medical Devices, News, Novartis, Stomach cancer, Prostate cancer, World Health Organization, Lung cancer, WHO, England, Government, GE Healthcare, Colon, Cancer, NHS England, Death, Woman, Diagnosis, Identity management, Growth, New Jersey Department of Health, Patient, Prevalence, Cancer Research UK, Quest Diagnostics, LabCorp, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Public Health England, Breast cancer, Medical device, Medical imaging, Marketing

A non-invasive cancer diagnosis is a method of detecting cancer conditions with just a small incision in the body.

Key Points: 
  • A non-invasive cancer diagnosis is a method of detecting cancer conditions with just a small incision in the body.
  • The most common new cases of cancer in 2020 include breast cancer (2.26 million), lung cancer (2.21 million), colon and rectum cancer (1.93 million), prostate cancer (1.41 million), stomach cancer (1.09 million), and others.
  • This significant number of cancer cases has shifted the global attention towards the adoption of early detection and diagnosis techniques for cancer.
  • Asia-Pacific is anticipated to hold a considerable growth in the global non-invasive cancer diagnosis market.

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Genetics, Genetic testing, LabCorp, Parkinson's disease, Heredity, Brain, Ascension, Benchmarking, Illumina, Inc., LRRK2, Epidemiology, Partnership, Genetic, Growth, Qiagen, Drug discovery, Prevalence, Software, Research, Cancer, Agriculture, Pharmaceutical industry, Vaccine, Audit, Medical imaging

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

The Clinical Trial Diversity Puzzle: How can the Industry do Better? Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, January 11, 2023
Headwater Diversion Plan (Jordan River), Clinical trial, Health, Research, Medidata Solutions, Diversity, Minister of Diversity, Inclusion and Youth, Patient engagement in Canada, Patient, Nextgen, Enrollment, Medical device, Pharmaceutical industry, LabCorp, MD

TORONTO, Ontario, Jan. 11, 2023 /PRNewswire-PRWeb/ -- The industry has faced the lack of clinical trial diversity head-on by working to improve access to clinical trials. However, making research accessible to underrepresented populations is only part of the solution. The webinar's core will be a discussion on how to reach and gain trust with underrepresented patients.

Key Points: 
  • As an industry we understand that diversity in clinical trials matters now more than ever.
  • Attendees will learn methods to overcome barriers and accelerate trust within underrepresented communities along with innovative approaches to accelerate inclusive patient recruitment.
  • TORONTO, Ontario, Jan. 11, 2023 /PRNewswire-PRWeb/ -- The industry has faced the lack of clinical trial diversity head-on by working to improve access to clinical trials.
  • Register to delve into the clinical trial diversity puzzle and find out how the industry can do better.

Thomas Pike to Join Labcorp as President and Chief Executive Officer of Its Drug Development Clinical Development Business Unit

Retrieved on: 
Thursday, January 5, 2023
Health, Science, Other Science, Pharmaceutical, Research, Chicago Board of Trade Independent Battery Light Artillery, Early Development of Global Education, EVP, Tom, Drug, Multimedia, Council for the Central Laboratory of the Research Councils, LH, Growth, Patient, NYSE, Development, Drug development, Management, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023.
  • Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp’s chairman and CEO Adam Schechter.
  • At the time of the spin-off, Mr. Pike will serve as the chief executive officer and chairman of the Board of the independent, publicly listed company.
  • In the coming months, Labcorp will announce the Board of Directors of the new company, including its lead independent director.

Labcorp to Speak at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Health, Hospitals, Clinical Trials, Research, Pharmaceutical, Science, Conference, NYSE, LH, Pharmaceutical industry, Broadcasting, Life insurance, LabCorp

Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).
  • A live audio webcast of the fireside chat will be available via the Company Investor Relations website at ir.Labcorp.com and archived for replay.